Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Kelly Mills MD, MHS

Kelly A. Mills MD, MHS

Associate Professor of Neurology, Division of Movement Disorders, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Kelly Mills is an Associate Professor of Neurology and the Director of the Johns Hopkins Neuromodulation and Advanced Therapies Clinic, Director of the Johns Hopkins Movement Disorders Division, and medical director of the Parkinson’s Foundation Center of Excellence.

Dr. Mills sees patients in the Johns Hopkins Neuromodulation and Advanced Therapies Clinic, where he evaluates patients who may need treatments such as deep brain stimulation or medication infusion therapies, and also works in the ataxia clinic, botulinum toxin injection clinic, general movement disorders clinic, and the palliative care clinic. He is Parkinson Study Group Investigator and has participated in several clinical trials for disease-modifying therapies in Parkinson’s disease. He researchers the neurobiological mechanisms of cognitive dysfunction in Parkinson’s disease, including cholinergic signaling and inflammation, using PET imaging. He is particularly interested in describing the role of the basal ganglia in cognition, and the impact various diseases have on cognition by affecting the basal ganglia and in describing how certain treatments, like DBS, might impact cognitive and psychiatric problems seen in movement disorders.

Dr. Mills also studies human brain neurophysiology through intraoperative recordings and collaborates with neurosurgeons and engineers on the development of the next generation of brain stimulation devices.


Dr. Mills receives research funding from UCB Pharma for his role as a clinical trial site PI.

Recent Contributions to PracticeUpdate:

  1. GLP-1 RA Lixisenatide for Early-Stage Parkinson’s Disease